NDAORALSOLUTION
Approved
Mar 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MYCIFRADIN (neomycin sulfate) by Pfizer is clinical pharmacology neomycin sulfate is poorly absorbed from the normal gastrointestinal tract. First approved in 2009.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYCIFRADIN (neomycin sulfate) is an oral aminoglycoside antibiotic that suppresses intestinal bacterial growth by inhibiting protein synthesis in susceptible gram-negative and some gram-positive organisms. Approximately 97% of the drug remains unabsorbed in the gastrointestinal tract, with rapid suppression of most intestinal bacteria persisting 48–72 hours post-dose. It is used primarily for preoperative bowel sterilization and hepatic encephalopathy management.
LOE Approaching
Product is in late-stage lifecycle approaching loss of exclusivity; commercial team likely focused on defending market share against generic entry and optimizing remnant market capture.
Mechanism of Action
CLINICAL PHARMACOLOGY Neomycin sulfate is poorly absorbed from the normal gastrointestinal tract.The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function. The unabsorbed portion of the drug (approximately 97%) is…
Indications
Worked on MYCIFRADIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.